✦ LIBER ✦

Paclitaxel, ifosfamide, and nedaplatin as second-line treatment for patients with metastatic urothelial carcinoma: A phase II study of the SUOC group

✍ Scribed by Hiroshi Kitamura; Keisuke Taguchi; Yasuharu Kunishima; Masahiro Yanase; Atsushi Takahashi; Masanori Shigyo; Toshiaki Tanaka; Masatoshi Mutoh; Fumimasa Fukuta; Naoya Masumori; Taiji Tsukamoto

Book ID: 108587046
Publisher: John Wiley and Sons
Year: 2011
Tongue: English
Weight: 148 KB
Volume: 102
Category: Article
ISSN: 1347-9032
DOI: 10.1111/j.1349-7006.2011.01909.x

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Weekly regimen of epirubicin and paclita

Weekly regimen of epirubicin and paclitaxel as second-line chemotherapy in patients with metastatic transitional cell carcinoma of urothelial tract: results of a phase II study

✍ Antonio Rozzi; Margherita Salerno; Francesca Bordin; Ferdinando De Marco; Stefan 📂 Article 📅 2010 🏛 Springer US 🌐 English ⚖ 316 KB

Phase II study of paclitaxel and epirubi

Phase II study of paclitaxel and epirubicin as first-line treatment in patients with metastatic nonsmall cell lung carcinoma

✍ Giovanni L. Ceresoli; Stefania Dell'Oro; Paolo Passoni; Eugenio Villa 📂 Article 📅 2000 🏛 John Wiley and Sons 🌐 English ⚖ 90 KB 👁 2 views

A Phase II study of paclitaxel and ifosf

A Phase II study of paclitaxel and ifosfamide for patients with advanced refractory carcinoma of the urothelium

✍ Christopher J. Sweeney; Stephen D. Williams; David E. Finch; Richard Bihrle; Ric 📂 Article 📅 1999 🏛 John Wiley and Sons 🌐 English ⚖ 62 KB 👁 2 views

## BACKGROUND. Cisplatin-based combination chemotherapy for patients with advanced transitional cell carcinoma (TCC) of the urothelium has limitations, and new therapies need to be evaluated. METHODS. Ifosfamide 1.0 gm/m 2 on Days 1-4 and paclitaxel 135 mg/m 2 by 24-hour infusion on Day 4 were ad

A phase II study of paclitaxel plus carb

A phase II study of paclitaxel plus carboplatin as first-line chemotherapy for women with metastatic breast carcinoma

✍ Edith A. Perez; David W. Hillman; Philip J. Stella; James E. Krook; Lynn C. Hart 📂 Article 📅 2000 🏛 John Wiley and Sons 🌐 English ⚖ 96 KB 👁 3 views

## BACKGROUND. This Phase II multicenter study evaluated the efficacy and toxicity of paclitaxel (200 mg/m 2 by 3-hour infusion) with carboplatin (area under the curve 6 mg/mL per minute) administered every 3 weeks as first-line therapy for women with metastatic breast carcinoma. ## METHODS. Eligi

Combination of Ifosfamide, Paclitaxel, a

Combination of Ifosfamide, Paclitaxel, and Cisplatin for the Treatment of Metastatic and Recurrent Carcinoma of the Uterine Cervix: A Phase II Study of the Hellenic Cooperative Oncology Group

✍ Meletios A. Dimopoulos; Christos A. Papadimitriou; Kyrillos Sarris; Gerassimos A 📂 Article 📅 2002 🏛 Elsevier Science 🌐 English ⚖ 52 KB

The combination of gemcitabine and carbo

The combination of gemcitabine and carboplatin as first-line treatment in patients with advanced urothelial carcinoma : A Phase II study of the Hellenic Cooperative Oncology Group

✍ Aristotle Bamias; Lia A. Moulopoulos; Aggelos Koutras; Gerassimos Aravantinos; G 📂 Article 📅 2006 🏛 John Wiley and Sons 🌐 English ⚖ 132 KB

## Abstract ## BACKGROUND The toxicity of platinum‐based combinations represents a common problem for patients with advanced urothelial carcinoma. The authors previously reported encouraging efficacy for the combination of carboplatin and gemcitabine in patients considered to be unfit for cisplati